| Literature DB >> 28765591 |
Bora Lee1,2, Sang Wook Lee3, Dae In Kim4, Jae Heon Kim5.
Abstract
The true HPV prevalence in the foreskins of infants and children has been little documented, but reporting on this prevalence is of great importance given its impact on the rationale for treating asymptomatic boys. We searched multiple databases from 1960 to 2016 for observational or prospective studies that reported on HPV prevalence in foreskins. We conducted a meta-analysis using a random-effects model to pool for HPV prevalence in the foreskins of infants and children. Eight studies, with a total of 556 infants and children with phimosis, were eligible for the meta-analysis. The pooled overall prevalence of general HPV, high-risk HPV, low-risk HPV, HPV 16/18, HPV 16, and HPV 18 were 17.3 (95%CI: 0.8-46.3), 12.1 (95% CI: 0.9-31.5), 2.4 (95% CI: 0.0-11.2), 4.8 (95% CI: 0.0-16.8), 1.7 (95% CI: 0.0-5.1), and 0 (95% CI: 0-0.5), respectively. The estimated HPV prevalence in foreskins was not zero among infants and children, which implies HPV transmission other than by sexual contact. Considering that high-risk HPV is detected in asymptomatic infants and children, future studies are warranted to determine whether preventive treatments in asymptomatic infants and children could be effective in preventing persistence or transmission of high-risk HPV.Entities:
Mesh:
Year: 2017 PMID: 28765591 PMCID: PMC5539194 DOI: 10.1038/s41598-017-07506-z
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Flow chart of the included studies.
Characteristics and results of the included studies.
| Author (year) | Location | No. of samples | Median age (Range) | Phimosis | Investigated HPV type | general HPV | HR-HPV | LR-HPV | HPV type | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 16/18 | 16 | 18 | |||||||||
| Balci | Turkey | 100 | 5.7 (0.2–9.0) | 55 | 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 | 9 | 9 | 0 | 3 | 3 | 0 |
| Maarof | Malaysia | 51 | 9.0 (4.0–12.0) | 2 | NA | 2 | 0 | 2 | 0 | 0 | 0 |
| Klinglmair | Austria | 121 | NA (0.0–10.0) | NA | 6, 11, 16, 18 | 98 | 55 | 43 | 55 | NA | NA |
| Pilatz | Germany | 82 | 4.1 (1.0–14.0) | 82 | 6, 11, 16, 18, 31, 33, 35, 39, 42, 44, 45, 51–54, 56, 58, 59, 61, 62, 66–68, 70, 72, 73, 81–84, 90, 91 | 0 | 0 | 0 | 0 | 0 | 0 |
| Martino | Austria | 50 | 5.5 (0.42–15) | NA | 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 | 6 | 6 | 0 | 6 | 6 | 0 |
| Verit | Turkey | 30 | 8.1a (4.0–11.0) | NA | 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 | 25 | 25 | 0 | 1 | NA | NA |
| Chen | Austria | 52 | Neonatesb | NA | NA | 0 | 0 | 0 | 0 | 0 | 0 |
| Roman | U.S. | 70 | Neonatesc | NA | 6, 11, 16, 18 | 3 | 2 | 3 | 2 | 2 | 0 |
NA, not available; LR, low-risk; HR, high-risk.
aMean; bSampled within hours of birth; cSampled within 3 days of birth.
Risk of bias for included studies.
| Author (year) | Location | Detailed reasons for selected population | Detailed description of sampling and measurement method | Risk of bias | |
|---|---|---|---|---|---|
| study participation | outcome measurement | ||||
| Balci | Turkey | The reasons for circumcision were primary phimosis and religious. | Yes | Low | Low |
| Maarof | Malaysia | Target cohort was used | No | Low | Unclear |
| Klinglmair | Austria | Male individuals (without HPV related lesions) after circumcision due to congenital (children, adolescents). | Yes | Low | Low |
| Pilatz | Germany | The boys were referred for urological consultation due to foreskin problems. | Yes | High | Low |
| Martino | Austria | All boys referred to the pediatric urology unit of our department for radical circumcision of primary phimosis and did not show any signs or symptoms suggestive of HPV infection. | Yes | Low | Low |
| Verit | Turkey | The reasons for circumcision were mostly religious, with hypospadias repair in 3 patients. | Yes | Low | Low |
| Chen | Austria | Consecutive neonates who underwent routine autopsy. | Yes | Low | Low |
| Roman | U.S. | Unselected infants undergoing routine circumcision | Yes | Low | Low |
Estimated prevalence by the random-effect model.
| Author (year) | No. of samples | Prevalence (95% CI)a | |||||
|---|---|---|---|---|---|---|---|
| general HPV | HR-HPV | LR-HPV | HPV16/18 | HPV16 | HPV18 | ||
| Balci | 100 | 9.0 (4.2–16.4) | 9.0 (4.2–16.4) | 0.0 (0.0–3.6) | 3.0 (0.6–8.5) | 3.0 (0.6–8.5) | 0.0 (0.0–3.6) |
| Maarof | 51 | 3.9 (0.5–13.5) | 0.0 (0.0–7.0) | 3.9 (0.5–13.5) | 0.0 (0.0–7.0) | 0.0 (0.0–7) | 0.0 (0.0–7.0) |
| Klinglmair | 121 | 81.0 (72.9–87.5) | 45.5 (36.4–54.8) | 35.5 (27.1–44.8) | 45.5 (36.4–54.8) | NA | NA |
| Pilatz | 82 | 0.0 (0.0–4.4) | 0.0 (0.0–4.4) | 0.0 (0.0–4.4) | 0.0 (0.0–4.4) | 0.0 (0.0–4.4) | 0.0 (0.0–4.4) |
| Martino | 50 | 12.0 (4.5–24.3) | 12.0 (4.5–24.3) | 0.0 (0.0–7.1) | 12.0 (4.5–24.3) | 12.0 (4.5–24.3) | 0.0 (0.0–7.1) |
| Verit | 30 | 83.3 (65.3–94.4) | 83.3 (65.3–94.4) NA† | 0.0 (0.0–11.6) | 3.3 (0.1–17.2) | NA | NA |
| Chen | 52 | 0.0 (0.0–6.9) | 0.0 (0.0–6.9) | 0.0 (0.0–6.9) | 0.0 (0.0–6.9) | 0.0 (0.0–6.9) | 0.0 (0.0–6.9) |
| Roman | 70 | 4.3 (0.9–12.0) | 2.9 (0.4–9.9) | 4.3 (0.9–12) | 2.9 (0.4–9.9) | 2.9 (0.4–9.9) | 0.0 (0.0–5.1) |
| Overall | 556 | 17.3 (0.8–46.3) | 12.1 (0.9–31.5) 5.9 (0.0–19.8) | 2.4 (0.0–11.2) | 4.8 (0.0–16.8) | 1.7 (0–5.1) | 0.0 (0.0–0.5) |
| Heterogeneity - I2 (%) | 98.2 (97.5–98.7) | 96.8 (95.3–97.8) 95.7 (93.2–97.3)† | 94.1 (90.5–96.3) | 95.2 (92.5–96.9) | 68.7 (26–86.7) | 0.0 (0.0–0.0) | |
| p-value | <0.001 | <0.001 < 0.001† | < 0.001 | < 0.001 | 0.007 | 1 | |
NA, not available; LR, low-risk; HR, high-risk; CI, confidence interval.
†This value is generated by omitting the study of Verit et al., which was proved to be outlier by Galbraith plot.
aThe process of meta-analysis with prevalence data: 1) transform the prevalence into a quantity (Freeman-Tukey variant of the arcsine square root transformed proportion), 2) calculate the pooled prevalence as the back-transformation of the weighted mean of the transformed prevalences using DerSimonian-Laird weights assuming the random-effect model.
Figure 2Prevalence of PCR-detected HPV infection. Forest plot diagram showing the pooled estimates for HPV prevalence for general HPV (A), high-risk HPV (B), low-risk HPV (C), HPV 16/18 (D), HPV 16 (E), and HPV 18 (F). The black square signifies the weighted mean of each estimate. All data provided are for continuous outcomes.
Figure 3Influential analysis of the prevalence of PCR-detected HPV infection. Forest plot diagram showing the pooled estimate for HPV prevalence after the exclusion of the relevant studies for each type on general HPV (A), high-risk HPV (B), low-risk HPV (C), HPV 16/18 (D), HPV 16 (E), and HPV 18 (F). The black square signifies the weighted mean of each estimate. All data provided are for continuous outcomes.
Figure 4Galbraith plot to spot outliers for estimated meta-prevalence of HPV.
Meta-regression analysis for the prevalence of HPV.
| Prevalence (dependent variable) | Location | Median age | Publication year | |||
|---|---|---|---|---|---|---|
| R2 (%)a | p-valueb | R2 (%)a | p-valueb | R2 (%)a | p-valueb | |
| general HPV | 0.00 | 0.606 | 0.00 | 0.267 | 0.00 | 0.399 |
| HR-HPV | 0.00 | 0.426 | 0.23 | 0.204 | 0.00 | 0.378 |
| LR-HPV | 0.00 | 0.611 | 0.00 | 0.934 | 0.00 | 0.913 |
| HPV 16/18 | 0.00 | 0.541 | 0.00 | 0.826 | 0.00 | 0.622 |
| HPV 16 | 0.00 | 0.758 | 0.00 | 0.888 | 0.00 | 0.864 |
| HPV 18 | NA | NA | NA | |||
NA, not available.
aThe amount of heterogeneity accounted for by the moderator.
bp-value for the Wald-type test of the moderator.
Figure 5Publication bias for the prevalence of PCR-detected HPV infection. Funnel plots for HPV 16/18. The black square signifies the weighted mean of each estimate. All data provided are for continuous outcomes.